Foreign exchange traders monitor screens in Tokyo, Japan. Picture: GETTY IMAGES/CARL COURT
The Cambridge, Massachusetts-based firm became the second drugmaker, after Pfizer, to announce promising trial data in the development of a vaccine to defeat the pandemic. Its shares gained 9.6% on the day. “Investors are looking further ahead in the pandemic development into 2021, instead of focusing on the challenging outbreak that’s taking place in the US and Europe now,” said Tai Hui, chief Asia market strategist, JPMorgan Asset Management.